IP Library Granted Patent US 7,754,767
Granted Patent B2
US 7,754,767 · App. 10/482,629 · Granted Jul 13, 2010

Method for treatment of premature ejaculation in humans

Assignee: Trinity Laboratories, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,754,767
App. No.
10/482,629
Granted
Jul 13, 2010
Kind
B2
Abstract

The present invention belongs to the fields of pharmacology, medicine and medicinal chemistry, and provides methods and compositions for treating sexual dysfunction; more particularly, the invention relates to treatment of premature ejaculation in humans.

Claims (9)

1. A method for delaying the onset of ejaculation in a male individual, comprising administering to the individual a pharmaceutical formulation consisting essentially of dextromethorphan, sildenafil, and acetaminophen in an amount effective to delay the onset of ejaculation by the individual during sexual intercourse, wherein said administration is oral, parenteral or by intracavernosal injection.

2. The method of claim 1 , wherein said administration is parenteral.

3. The method of claim 1 , wherein said administration is by intracavernosal injection.

4. A method for delaying the onset of ejaculation in a male individual who has a premature ejaculation problem, comprising administering to the individual a pharmaceutical formulation consisting essentially of a combination of sildenafil, dextromethorphan, and acetaminophen in an amount effective to delay the onset of ejaculation by the individual during sexual intercourse, wherein the formulation is administered orally, parenterally or by intracavernosal injection.

5. The method of claim 4 , wherein the formulation is administered parenterally.

6. The method of claim 4 , wherein the formulation is administered by intracavernosal injection.

7. The method of claim 4 , wherein the sildenafil, dextromethorphan, and acetaminophen are administered combined in a single dosage form.

8. The method of claim 1 , wherein the pharmaceutical formulation consists of dextromethorphan, sildenafil and acetaminophen in an amount effective to delay the onset of ejaculation by the individual during sexual intercourse, and a pharmaceutically acceptable carrier or excipient.

9. The method of claim 4 , wherein the pharmaceutical formulation consists of dextromethorphan, sildenafil and acetaminophen in an amount effective to delay the onset of ejaculation by the individual during sexual intercourse, and a pharmaceutically acceptable carrier or excipient.

Assignments (4)
SECURITY INTEREST Recorded May 3, 2018
From: TRINITY LABORATORIES, INC.
To: JEFFERSON BANK
Reel/Frame 045710/0965 →
SECURITY INTEREST Recorded May 3, 2018
From: JEFFERSON BANK
To: LUMINUS BIOSCIENCES, INC.
Reel/Frame 045711/0157 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2008
From: AZAYA THERAPEUTICS, INC.
To: TRINITY LABORATORIES, INC.
Reel/Frame 020404/0965 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 24, 2003
From: SINGH, CHANDRA U.
To: AZAYA THERAPEUTIC, INC.
Reel/Frame 015611/0580 →
Continuity (2)
Provisional Application 6042422900 · Nov 6, 2002
Related Publication 20040235954A1 · Nov 25, 2004